185 related articles for article (PubMed ID: 3000280)
1. Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
Ruberg M; Javoy-Agid F; Hirsch E; Scatton B; LHeureux R; Hauw JJ; Duyckaerts C; Gray F; Morel-Maroger A; Rascol A
Ann Neurol; 1985 Nov; 18(5):523-9. PubMed ID: 3000280
[TBL] [Abstract][Full Text] [Related]
2. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
Kish SJ; Chang LJ; Mirchandani L; Shannak K; Hornykiewicz O
Ann Neurol; 1985 Nov; 18(5):530-6. PubMed ID: 2416269
[TBL] [Abstract][Full Text] [Related]
3. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
Bokobza B; Ruberg M; Scatton B; Javoy-Agid F; Agid Y
Eur J Pharmacol; 1984 Mar; 99(2-3):167-75. PubMed ID: 6734727
[TBL] [Abstract][Full Text] [Related]
4. Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
Garvey J; Petersen M; Waters CM; Rose SP; Hunt S; Briggs R; Jenner P; Marsden CD
Mov Disord; 1986; 1(2):129-34. PubMed ID: 3143064
[TBL] [Abstract][Full Text] [Related]
5. Progressive supranuclear palsy: postmortem chemical analysis.
Young AB
Ann Neurol; 1985 Nov; 18(5):521-2. PubMed ID: 2866753
[No Abstract] [Full Text] [Related]
6. Brain neurotransmitters and neuropeptides in Parkinson's disease.
Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P
Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688
[TBL] [Abstract][Full Text] [Related]
7. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
[TBL] [Abstract][Full Text] [Related]
8. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
9. Striatal dopamine deficiency in Parkinson's disease: role of aging.
Scherman D; Desnos C; Darchen F; Pollak P; Javoy-Agid F; Agid Y
Ann Neurol; 1989 Oct; 26(4):551-7. PubMed ID: 2817829
[TBL] [Abstract][Full Text] [Related]
10. Chemical neurotransmission in the parkinsonian brain.
Rinne UK; Rinne JO; Rinne JK; Laakso K
Med Biol; 1987; 65(2-3):75-81. PubMed ID: 2821331
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of selective lesions of cholinergic and dopaminergic neurons on serotonin-type 1 receptors in rat brain.
Quirion R; Richard J
Synapse; 1987; 1(1):124-30. PubMed ID: 3145578
[TBL] [Abstract][Full Text] [Related]
12. Dopamine and homovanillic acid concentrations in striatal and limbic regions of human brain.
Walsh FX; Stevens TJ; Langlais PJ; Bird ED
Ann Neurol; 1982 Jul; 12(1):52-5. PubMed ID: 7114818
[TBL] [Abstract][Full Text] [Related]
13. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
Melamed E; Hefti F; Wurtman RJ
Isr J Med Sci; 1982 Jan; 18(1):159-63. PubMed ID: 6121770
[TBL] [Abstract][Full Text] [Related]
14. Brain enkephalin receptors in Parkinson's disease.
Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
[TBL] [Abstract][Full Text] [Related]
15. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.
Ahlskog JE; Richelson E; Nelson A; Kelly PJ; Okazaki H; Tyce GM; van Heerden JA; Stoddard SL; Carmichael SW
Ann Neurol; 1991 Aug; 30(2):185-91. PubMed ID: 1654766
[TBL] [Abstract][Full Text] [Related]
16. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Tong J; Fitzmaurice PS; Ang LC; Furukawa Y; Guttman M; Kish SJ
Ann Neurol; 2004 Jan; 55(1):125-9. PubMed ID: 14705122
[TBL] [Abstract][Full Text] [Related]
17. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
18. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
Mogi M; Kondo T; Mizuno Y; Nagatsu T
Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
[TBL] [Abstract][Full Text] [Related]
19. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
Chinaglia G; Alvarez FJ; Probst A; Palacios JM
Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
[TBL] [Abstract][Full Text] [Related]
20. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
